Detection of Microdeletions in the Azoospermia Factor (AZF) Regions in Infertile Male Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03497728|
Recruitment Status : Recruiting
First Posted : April 13, 2018
Last Update Posted : April 13, 2018
|Condition or disease|
|Azoospermia or Severe Oligozoospermia|
Infertility has plagued more than 10% of the world's couples of childbearing age, of which male factors account for half. There are many causes of male infertility, including infection, genital malformations, immune dysfunction, varicocele, erectile dysfunction, drug side effect and chromosomal abnormality. Microdeletion of Azoospermia factor (AZF) in the long arm of the Y chromosome is one of the main genetic factors leading to dyszoospermia. The incidence of AZF microdeletions is 2%~19.4% among male infertile patients in Asia, which is related to the inclusion criteria, STS site selection, population and genetic background.
At present, there are large numbers of studies on AZF microdeletions in male infertility, and provide rich information on male infertility. However, as the main means of detection is multiplex PCR-capillary electrophoresis method, which usually detects sequence-tagged sites(STS) such as AZFa-sY84，sY86，AZFb-sY127，sY134，AZFc- sY1191, sY1291, sY1189,sY254 and sY255, information on other loci is still lacking.
In addition, the shortcomings of this method include false positive and false negative results caused by fuzzy electrophoresis strip or pollution and the presence of high repetition and a large number of palindrome in complex AZF region. Because some microdeletions can't be detected it is difficult to make an accurate judgement on the fertility of the patients.
This study will use Multiplex ligation-dependent probe amplification and NGS method to improve the detection rate of AZF microdeletion, and analyze the microdeletion data and the patient's fertility results, so as to improve genetic counseling. A total of 5000 male infertility patients will be enrolled. At least 1000 parents and 1000 normal fertile men will be asked to donate their peripheral blood for DNA.
In addition, in patients with azoospermia or severe oligozoospermia, the overall deletion rate of AZF is about 8.77% (1.75%-24.70%), so there are other unknown genetic factors leading to azoospermia or severe oligozoospermia. This study will also try to make a preliminary study of these factors.
|Study Type :||Observational|
|Estimated Enrollment :||5000 participants|
|Official Title:||Detection of Microdeletions in the Azoospermia Factor (AZF) Regions on the Human Y Chromosome in Infertile Male Patients|
|Actual Study Start Date :||December 4, 2017|
|Estimated Primary Completion Date :||September 1, 2018|
|Estimated Study Completion Date :||December 1, 2018|
- frequency of mirodeletion [ Time Frame: through study completion, an average of 1 year ]The propotion of azoospermia patients with AZF mirodeletion
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03497728
|Contact: Yueqiu Tanfirstname.lastname@example.org|
|Reproductive & Genetic Hospital of CITIC-XIANGYA||Recruiting|
|Changsha, Hunan, China, 410000|
|Contact: YueQiu Tan +86-731-82355100 email@example.com|
|Study Chair:||Yueqiu Tan||Reproductive & Genetic Hospital of CITIC-Xiangya|